Clinical Trial Update: The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib [Phase 2]

View source ↗

Summary

Phase 2 trial assessing whether EGFR mutation status influences outcomes in metastatic pancreatic cancer patients treated with gemcitabine, with or without erlo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: UNKNOWN